Facial plast Surg 2004; 20(2): 129-134
DOI: 10.1055/s-2004-861753
Copyright © 2004 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001 USA.

Cymetra

Brian P. Maloney1 , Brent A. Murphy2 , Harvey P. Cole3  III 
  • 1The Maloney Center for Facial Plastic Surgery, Atlanta, Georgia
  • 2Vanderbilt Opthalnic and Facial Plastic Surgery Fellowship Program, Vanderbilt Medical Center, Nashville, Tennessee
  • 3Emory University Medical Center, Atlanta, Georgia
Further Information

Publication History

Publication Date:
11 January 2005 (online)

ABSTRACT

Soft tissue replacement using a filler as a temporary scaffold to encourage revascularization and tissue in growth is an exciting concept. Sheets of acellular human dermal matrix, called Alloderm (Lifecell Corp, Branchburg, NJ), have been shown to do just that. When implanted into a patient, tissue growth and revascularization have both been observed.[1] [2] The company manufactures a micronized or injectable form called Cymetra. This article reviews the manufacturing, tissue interaction, clinical applications, and anticipated clinical results.